Claims for Patent: 7,550,595

Summary for Patent: 7,550,595

Title:	Biphenyl compounds useful as muscarinic receptor antagonists
Abstract:	This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Inventor(s):	Mathai Mammen, Yu-Hua Ji, YongQi Mu, Craig Husfeld, Li Li
Assignee:	Theravance Biopharma R&D IP LLC
Application Number:	US11/880,002
Patent Claims:	1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the formula: wherein: a is 0 or 1; R1 is halo; b is 0 or 1; R2 is halo; m is 0 or 1; R4 is selected from hydrogen and (1-4C)alkyl; s is 0, 1 or 2; Ar1 represents a phenylene group substituted with (R5)q where q is 0 or an integer from 1 to 4 and each R5 is independently selected from halo, hydroxy, (1-4C)alkyl, and (1-4C)alkoxy; t is 0, 1 or 2; n is 0 or an integer from 1 to 3; p is 0 or 1; and R7 and R8 are independently hydrogen or (1-4C)alkyl; wherein each alkyl group in R5, R7, and R8 is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or stereoisomer thereof. 2. The pharmaceutical composition of claim 1, wherein m is 0, s is 0 and t is 1. 3. The pharmaceutical composition of claim 1, wherein Ar1 represents phen-1,3-ylene or phen-1,4-ylene, optionally substituted with one or two R5 substituents. 4. The pharmaceutical composition of claim 1, wherein R4 is selected from hydrogen, methyl and ethyl. 5. The pharmaceutical composition of claim 1, wherein R7 is selected from hydrogen, methyl, ethyl, n-propyl and isopropyl; and R8 is hydrogen. 6. The pharmaceutical composition of claim 1, wherein R7 and R8 are ethyl. 7. The pharmaceutical composition of claim 1, wherein a and b each represent 0; m is 0; s is 0; t is 1; Ar1 represents phen-1,4-ylene optionally substituted with one or two R5 substituents; n is 2 and the —CONR7R8 group is in the para position; and R8 is hydrogen. 8. The pharmaceutical composition of claim 7, wherein R5 is independently selected from halo, (1-4C)alkyl, and (1-4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents. 9. The pharmaceutical composition of claim 1, wherein the compound is biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester or a pharmaceutically acceptable salt thereof. 10. The pharmaceutical composition of claim 1, which is suitable for administration by inhalation. 11. The pharmaceutical composition of claim 10, which is in the form of an aerosol. 12. The pharmaceutical composition of claim 10, which is in the form of a powder. 13. The pharmaceutical composition of claim 10, which is in the form of a solution. 14. The pharmaceutical composition of claim 10, wherein the compound is micronized. 15. The pharmaceutical composition of claim 14, wherein the compound is combined with the carrier to form a suspension. 16. The pharmaceutical composition of claim 15, wherein the carrier is an isotonic aqueous solution. 17. The pharmaceutical composition of claim 14, wherein the compound is combined with the carrier to form a free flowing powder. 18. The pharmaceutical composition of claim 17, wherein the carrier is lactose or starch. 19. The pharmaceutical composition of claim 10, which further comprises a liquefied propellant. 20. The pharmaceutical composition of claim 10, which is administered using a nebulizer inhaler. 21. The pharmaceutical composition of claim 10, which is administered using a metered-dose inhaler. 22. The pharmaceutical composition of claim 10, which is administered using a dry powder inhaler.